Featured Experience
Artificial Intelligence
In the rapidly evolving world of artificial intelligence (AI), safeguarding your intellectual property (IP) is critical. As a market and thought leader in the technology sector, Sterne Kessler helps clients develop comprehensive IP solutions that protect innovation, foster growth, and maximize value. Whether you are an emerging startup company or a well-established technology pioneer, we are committed to helping you harness the full potential of AI technology.
Pharmaceutical Patent Litigation
At Sterne Kessler, we know what it takes to win across any venue in pharmaceutical IP litigation. Our award-winning team has a deep bench of experienced litigators representing biosimilars as well as generic and specialty brand pharmaceutical companies in high-profile patent litigation, including blockbuster Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters.
ITC Litigation
With one of the nation’s top ITC practices, Sterne Kessler offers unrivaled experience, comprehensive litigation strategy, and the legal and technical know-how to achieve the best possible results. In the last five years, Sterne Kessler has handled more cases at the ITC than 90% of firms appearing before the Commission.
Design Patents
For nearly four decades, Sterne Kessler has been at the forefront of design patents, consistently delivering successful outcomes for clients in securing and defending their design rights. We develop effective, comprehensive IP programs to protect some of the most iconic product designs in the world and to eliminate knock-offs in the marketplace.
Featured News
More News & InsightsOld Drugs, New Tricks: Repurposing Through 505(b)(2) Submissions
Summer Associates Hannah Jankunis and Matthew Swazer also contributed to this article. FDA DRUG APPROVAL PATHWAYS 505(b)(1) New Drug Application De novo drug development is costly and time…
Subject Matter Eligibility of AI Innovations—USPTO’s Updated Guidance
This article discusses the July 17, 2024 guidance[1] issued by the United States Patent and Trademark Office (“USPTO”) regarding the subject matter eligibility of patent claims involving artificial…
A Look at the PTAB’s Assessment of Prior Art Exceptions
Under the Leahy-Smith America Invents Act, Title 35 of the U.S. Code, Section 102(a), prior art is determined based on the effective filing date of the claimed invention,…
Sterne Kessler Achieves Mansfield Rule Certification for 2023-24
Washington, D.C. (October 2, 2024) – Sterne, Kessler, Goldstein & Fox is proud to announce that the firm has earned Mansfield Certification for 2023-2024. This accomplishment underscores the…
Sterne Kessler Successfully Defends G+ Communications’ 5G Patent in Ex Parte Reexamination with $61M on the Line
Sterne, Kessler, Goldstein & Fox announces that it has successfully defended G+ Communications LLC in an ex parte reexamination (Case No. 90/019,347) filed by Samsung Electronics against U.S.…
Treading New Ground: Sterne Kessler Secures First Denial of a Design Patent IPR Petition Since LKQ v. GM
Sterne, Kessler, Goldstein & Fox secured the first denial of an inter partes review petition at the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB)…
Your innovations are worth the best protection
Expertise
Sterne Kessler is a full-service IP firm that delivers innovative solutions tailored to your business and industry.